The efficacy of [18F]FDG PET/CT in monitoring disease progression in malignant pleural mesothelioma La eficacia de [18F]FDG PET/TC en el seguimiento de la progresión de la enfermedad en el mesotelioma pleural maligno


Söyler Y., ÖZMEN Ö., AKIN KABALAK P., ERTÜRK H., Uğurman F., Yılmaz Ü.

Revista Espanola de Medicina Nuclear e Imagen Molecular, cilt.42, sa.1, ss.3-9, 2023 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 42 Sayı: 1
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1016/j.remn.2022.06.005
  • Dergi Adı: Revista Espanola de Medicina Nuclear e Imagen Molecular
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, DIALNET
  • Sayfa Sayıları: ss.3-9
  • Anahtar Kelimeler: 18F-FDG PET/CT, Computed tomography, Follow-up strategies, Malignant pleural mesothelioma, Tumour SUVmax
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: In the event of suspicion of malignant pleural mesothelioma (MPM) progression, imaging plays an important role. We aimed to evaluate the efficacy of [18F]FDG PET/CT in monitoring disease progression by comparing it with CT, and estimate median overall survival (OS) according to progression status with CT and [18F]FDG PET/CT. Materials and Methods: This was an observational, retrospective, single-institution study with MPM patients who had both [18F]FDG PET/CT and CT for monitoring disease progression from March 2009 to February 2020. Clinical features, radiological findings, and progression status according to CT [radiologic progression negative (RPN), radiologic progression positive (RPP)] and [18F]FDG PET/CT [metabolic progression negative (MPN), metabolic progression positive (MPP)] were recorded. The discrepancies and concordance between two methods were evaluated. The OS was estimated using the Kaplan–Meier method. Results: A total of 56 patients were included. There were thirty-one (55.3%) RPN and 25 (44.7%) RPP, while there were 26 (46.5%) MPN and 30 (53.5%) MPP. All RPP patients were also found to be MPP, however, among RPN, 5 patients (8.9% of all patients) were evaluated as MPP. The concordance between two methods in monitoring disease progression was very good (K=.423; P<.01). The OS was 26 ± 2.6 months in all patients. Kaplan-Meier curves between RPN and RPP, and between MPN and MPP did not show statistically significant differences (P=.56 and P=.25, respectively). Conclusions: Both methods are equally acceptable in monitoring disease progression in MPM, even though [18F]FDG PET/CT detected more progression than CT did.